3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
3
Lymphoid
3
Genitourinary
3
Thoracic
2
Other hematologic neoplasm
2
Gastrointestinal
2
Endocrine
2
CNS
2
Sarcoma
1
NET
1
Head & Neck
1
Gynecologic
1
Dermatologic
1
Breast
1
Conditions
Thyroid Neoplasms
2
Thyroid Cancer, Papillary
1
Thoracic Neoplasms
1
Sarcoma
1
Salivary Gland Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms by Site
1
Neoplasms
1
Melanoma
1
Lymphoma, Large-Cell, Anaplastic
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Digestive System Neoplasms
1
Digestive System Diseases
1
Colorectal Neoplasms
1
Colonic Diseases
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Bronchogenic
1
Bronchial Neoplasms
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
pembrolizumab
33
Cetuximab
16
Cisplatin
10
Radiotherapy
8
Paclitaxel
8
Docetaxel
8
atezolizumab
7
Fluorouracil
7
cemiplimab
6
Drug Therapy
6
budigalimab
5
Gemcitabine
5
Cyclophosphamide
5
Blood Specimen Collection
5
trametinib
4
Pemetrexed
4
Nivolumab
4
Magnetic Resonance Spectroscopy
4
Bleomycin
4
Bevacizumab
4
palbociclib
3
fludarabine
3
durvalumab
3
dabrafenib
3
avelumab
3
Trastuzumab
3
Oxaliplatin
3
Interleukin-2
3
Indocyanine Green
3
Immunotherapy
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
alectinib
×
Head & Neck
×
Clear all
NCT04644315
2023-08-07
ALpha-T
Hoffmann-La Roche
Phase 2
Terminated
1 enrolled
5 charts